Medivir

Company Description

---

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors.

Year founded

---

1988

Headquarters

---

Lunastigen 5, 2nd floor, 14122 Huddinge – Sweden

Shares outstanding

---

55,735,651

IPO

---

Jan. 1, 2000

Stock exchange(s)

---

Nasdaq Stockholm